Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Selling, General & Admin · Q3 FY2026 · quarter ended Mar 2026

Selling, general & admin of $7.92M in Q3 FY2026

Q3 FY2026 selling, general & admin was $7.92M. Trailing-twelve-month selling, general & admin was $33.33M. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Selling, general & admin amounted to 34.2% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $24.35M (-44.7%) for the fiscal year ending May 2026, a slowdown from the +8.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.92M+5.0% QoQ
Last fiscal yearMay 2025
$44.05M+8.9% YoY
LTMMar 2026
$33.33M— YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+8.9%-44.7%-53.6 pp
3-year CAGR+8.3%-1.4%-9.7 pp
5-year CAGR+6.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
44.05M USD
Year-over-year change
+8.9%
4-year CAGR
+12.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Selling, general & admin amounts to 24.7% of revenue for LFCR, versus a peer median of 110.8%.
LFCR Competitors
Selling, General & Admin for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$166.84M CAD+0.2%+0.7%53.7%
CGCCanopy Growth CorporationLTM Mar 2026CA$134.01M CAD+10.1%-9.2%42.9%
SGHTSight Sciences, Inc.LTM Mar 2026$91.48M USD-7.4%-9.4%115.0%
CVRXCVRx, Inc.LTM Mar 2026$88.81M USD+5.3%+20.9%150.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$33.33M USD—+8.3%24.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M USD+76.0%+43.8%—
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.13M USD-1.6%-10.3%64.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding LFCR) —+5.3%+0.7%110.8%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.